

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

RMC2C

RRID:CVCL_B3PS

Type: Cell Line

Proper Citation

RRID:CVCL_B3PS

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_B3PS

Proper Citation: RRID:CVCL_B3PS

Description: Cell line RMC2C is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Kidney medullary carcinoma

Defining Citation: [PMID:32359397](#)

Comments: Karyotypic information: Near hypertriploid karyotype (PubMed=32359397)., Population: African American.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: RMC2C

Cross References: Wikidata:Q110433170

ID: CVCL_B3PS

Record Creation Time: 20220427T221502+0000

Record Last Update: 20260905T182222+0000

Ratings and Alerts

No rating or validation information has been found for RMC2C.

No alerts have been found for RMC2C.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Msaouel P, et al. (2025) Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling. Cell reports. Medicine, 6(11), 102423.

Grimm SL, et al. (2025) CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(6), 1057.

Zacharias NM, et al. (2025) Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma. Molecular cancer therapeutics.